0000000000618662

AUTHOR

Luis Bataller

showing 7 related works from this author

Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma

2016

We aimed to identify new cell-membrane antigens implicated in opsoclonus-myoclonus with neuroblastoma. The sera of 3 out of 14 patients showed IgG electron-microscopy immunogold reactivity on SH-SY5Y neuroblastoma cells. Immunoprecipitation experiments using rat brain synaptosomes and SH-SY5Y cells led to the identification of: (1) thirty-one nuclear/cytoplasmic proteins (including antigens HuB, HuC); (2) seven neuronal membrane proteins, including the Shaw-potassium channel Kv3.3 (KCNC3), whose genetic disruption in mice causes ataxia and generalized muscle twitching. Although cell-based assays did not demonstrate direct antigenicity, our findings point to Shaw-related subfamily of the pot…

Central Nervous SystemMale0301 basic medicineAntigenicityDatabases FactualThymomaImmunoprecipitationKCTD7Cell Adhesion Molecules NeuronalImmunologyNerve Tissue ProteinsBiologyNeuroblastoma03 medical and health sciences0302 clinical medicineAntigenCell Line TumorNeuroblastomaOpsoclonus myoclonus syndromemedicineAnimalsHumansImmunology and AllergyRats WistarChildOpsoclonus-Myoclonus SyndromeBrain NeoplasmsMembrane ProteinsNuclear ProteinsImmunogold labellingmedicine.diseaseMolecular biologyRatsHEK293 Cells030104 developmental biologyShaw Potassium ChannelsNeurologyMembrane proteinEncephalitisFemaleNeurology (clinical)030217 neurology & neurosurgerySynaptosomesJournal of Neuroimmunology
researchProduct

Clinical manifestations of the anti-IgLON5 disease

2017

Objective:To report the presentation, main syndromes, human leukocyte antigen (HLA) association, and immunoglobulin G (IgG) subclass in the anti-IgLON5 disease: a disorder with parasomnias, sleep apnea, and IgLON5 antibodies.Methods:This was a retrospective clinical analysis of 22 patients. The IgG subclass was determined using reported techniques.Results:Patients' median age was 64 years (range 46–83). Symptoms that led to initial consultation included sleep problems (8 patients; 36%), gait abnormalities (8; 36%), bulbar dysfunction (3; 14%), chorea (2; 9%), and cognitive decline (1; 5%). By the time of diagnosis of the disorder, 4 syndromes were identified: (1) a sleep disorder with paras…

Sleep Wake Disorders0301 basic medicinemedicine.medical_specialtyCell Adhesion Molecules NeuronalPopulationExcessive daytime sleepinessAutoimmune DiseasesProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCognitive declineeducationAgedAutoantibodiesRetrospective StudiesAged 80 and overeducation.field_of_studySleep disorderbusiness.industryBrainSleep apneaChoreaParasomniaMiddle Agedmedicine.disease030104 developmental biologyImmunoglobulin GImmunotherapyNeurology (clinical)medicine.symptomCarrier ProteinsbusinessBiomarkers030217 neurology & neurosurgeryHLA-DRB1 ChainsNeurology
researchProduct

Charcot-Marie-Tooth disease: Genetic and clinical spectrum in a Spanish clinical series

2013

Objectives: To determine the genetic distribution and the phenotypic correlation of an extensive series of patients with Charcot-Marie-Tooth disease in a geographically well-defined Mediterranean area. Methods: A thorough genetic screening, including most of the known genes involved in this disease, was performed and analyzed in this longitudinal descriptive study. Clinical data were analyzed and compared among the genetic subgroups. Results: Molecular diagnosis was accomplished in 365 of 438 patients (83.3%), with a higher success rate in demyelinating forms of the disease. The CMT1A duplication (PMP22 gene) was the most frequent genetic diagnosis (50.4%), followed by mutations in the GJB1…

Foot DeformitiesMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyDNA Mutational AnalysisNerve Tissue ProteinsDiseaseArticleConnexinsCentral nervous system diseaseDegenerative diseasestomatognathic systemCharcot-Marie-Tooth DiseaseGene duplicationHumansMedicineLongitudinal StudiesMuscle StrengthGeneRetrospective StudiesGeneticsSeries (stratigraphy)business.industryRetrospective cohort studymedicine.diseasePhenotypeMuscular Atrophystomatognathic diseasesSpainMutationSensation DisordersFemaleNeurology (clinical)businessMyelin ProteinsNeurology
researchProduct

Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

2013

Paraneoplastic myelitis is a rare inflammatory disorder most frequently associated with solid tumors or lymphoproliferative disorders. Patients often harbor onconeuronal antibodies and their prognosis is usually poor. Here we report a 42-year old woman with longitudinally extensive transverse myelitis and aquaporin-4 (AQP4) antibodies that led to the diagnosis of ovarian teratoma. After tumor removal and immune therapy (including corticosteroids, plasma exchange, intravenous immunoglobulins and rituximab) the patient progressively improved achieving complete recovery. Histological study of the teratoma demonstrated neural tissue containing AQP4 expressing cells and intense inflammatory infi…

AdultPathologymedicine.medical_specialtyImmunologyLymphoproliferative disordersMyelitis TransverseAutoimmune diseases Paraneoplastic syndrome Transverse myelitisTransverse myelitisDiagnosis DifferentialmedicineImmunology and AllergyHumansNeurociènciesOvarian TeratomaAutoantibodiesAquaporin 4Ovarian Neoplasmsbiologybusiness.industryParaneoplastic MyelitisTeratomamedicine.diseaseNeurologybiology.proteinRituximabFemaleSistema nerviós MalaltiesNeurology (clinical)TeratomaAntibodybusinessBiomarkersmedicine.drugInflammatory disorder
researchProduct

Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.

2017

Objective:To identify cell-surface antibodies in patients with neuromyotonia and to describe the main clinical implications.Methods:Sera of 3 patients with thymoma-associated neuromyotonia and myasthenia gravis were used to immunoprecipitate and characterize neuronal cell-surface antigens using reported techniques. The clinical significance of antibodies against precipitated proteins was assessed with sera of 98 patients (neuromyotonia 46, myasthenia gravis 52, thymoma 42; 33 of them with overlapping syndromes) and 219 controls (other neurologic diseases, cancer, and healthy volunteers).Results:Immunoprecipitation studies identified 3 targets, including the Netrin-1 receptors DCC (deleted i…

0301 basic medicineAdultMaleThymomaNeuromyotoniaDeleted in Colorectal CancerThymomaCell Adhesion Molecules NeuronalNerve Tissue ProteinsReceptors Cell SurfaceTransfectionArticle03 medical and health sciences0302 clinical medicineAntigenMyasthenia GravismedicineHumansImmunoprecipitationNerve Growth FactorsReceptorMuscle SkeletalNeural Cell Adhesion MoleculesAgedAutoantibodiesbiologybusiness.industryElectromyographyTumor Suppressor ProteinsCalcium-Binding ProteinsAutoantibodyMembrane ProteinsThymus NeoplasmsMiddle AgedNetrin-1medicine.diseaseDCC ReceptorMagnetic Resonance ImagingMyasthenia gravis030104 developmental biologyHEK293 CellsImmunologybiology.proteinFemaleNeurology (clinical)AntibodybusinessNetrin Receptors030217 neurology & neurosurgeryNeurology
researchProduct

Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.

2021

Spastic paraplegia type 7 (SPG7) is one of the most common hereditary spastic paraplegias. SPG7 mutations most often lead to spastic paraparesis (HSP) and/or hereditary cerebellar ataxia (HCA), frequently with mixed phenotypes. We sought to clinically and genetically characterize a Spanish cohort of SPG7 patients. Patients were recruited from our HCA and HSP cohorts. We identified twenty-one patients with biallelic pathogenic SPG7 mutations. Mean age at onset was 37.4 years (SD ± 14.3). The most frequent phenotype was spastic ataxia (57%), followed by pure spastic paraplegia (19%) and complex phenotypes (19%). Isolated patients presented with focal or multifocal dystonia, subclinical myopat…

medicine.medical_specialtyNeurogeneticsCompound heterozygosityGastroenterologyInternal medicinemedicineSpasticHumansMyopathySubclinical infectionDystoniaCerebellar ataxiabusiness.industrySpastic Paraplegia HereditaryMetalloendopeptidasesmedicine.diseasenervous system diseasesOptic AtrophyPhenotypeNeurologyMutationATPases Associated with Diverse Cellular ActivitiesNeurology (clinical)medicine.symptombusinessSpastic paraplegia type 7Journal of the neurological sciences
researchProduct

Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen–Matched Sibling Transp…

2016

We analyzed the incidence, clinical characteristics, prognostic factors, and outcome of central nervous system (CNS) infections in consecutive patients with receiving umbilical cord blood transplantation (UCBT) (n = 343) or HLA-matched sibling donor stem cell transplantation (MST) (n = 366). Thirty-four CNS infections were documented at a median time of 116 days after transplantation (range, 7 to 1161). The cumulative incidence (CI) risk of developing a CNS infection was .6% at day +30, 2.3% at day +90, and 4.9% at 5 years. The 5-year CI of CNS infection was 8.2% after UCBT and 1.7% after MST (P  .001). The causative micro-organisms of CNS infections were fungi (35%), virus (32%), Toxoplasm…

Adultmedicine.medical_specialtyTime FactorsAdolescentCentral nervous systemHuman leukocyte antigenGastroenterologyYoung Adult03 medical and health sciencesCentral Nervous System Infections0302 clinical medicineHLA AntigensInternal medicinemedicineHumansCumulative incidenceAgedTransplantationbusiness.industryUmbilical Cord Blood TransplantationIncidenceSiblingsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationBacterial InfectionsHematologyMiddle Agedmedicine.diseaseTransplantationmedicine.anatomical_structureMycosesVirus DiseasesHistocompatibility030220 oncology & carcinogenesisImmunologyCord Blood Stem Cell TransplantationStem cellUnrelated DonorsbusinessToxoplasmosisEncephalitis030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct